CTLA4 and cancer: Immunotherapy has now become a standard of care in many cancer settings during the last decade with the introduction of specific antibodies blocking immune checkpoint molecules, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and programed death 1/programed death-ligand 1 (PD-1/PD-L1) among other burgeoning immune checkpoint pathway inhibitors arriving to the clinic [99].